Krsnaa Diagnostics Limited (IN:KRSNAA)
:KRSNAA
Want to see IN:KRSNAA full AI Analyst Report?
Top Page
Krsnaa Diagnostics Limited
(KRSNAA)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹650.00
▼(-11.58% Downside)
Action:ReiteratedDate:03/24/26
The score is anchored by solid financial performance (growth, strong margins, and low leverage), but is materially held back by weak technicals (broad downtrend) and a relatively high valuation (P/E 38.37) with a low dividend yield.
Positive Factors
High gross margins
Sustained gross margins near 76% indicate durable pricing power and efficient test-cost structure across pathology and imaging. This margin buffer supports profitability through tariff variability, funds expansion of lab network, and improves operating leverage as volumes scale over months.
Negative Factors
Negative free cash flow
Negative FCF despite solid operating cash conversion signals that investment timing and capital deployment are outpacing cash generation. Persisting FCF deficits can limit organic reinvestment, slow deleveraging, or force external funding, affecting financial resilience over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 76% indicate durable pricing power and efficient test-cost structure across pathology and imaging. This margin buffer supports profitability through tariff variability, funds expansion of lab network, and improves operating leverage as volumes scale over months.
Read all positive factors
Krsnaa Diagnostics Limited (KRSNAA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹18.82B
Dividend Yield0.38%
Average Volume (3M)12.28K
Price to Earnings (P/E)38.4
Beta (1Y)1.07
Revenue Growth9.88%
EPS Growth6.01%
CountryIN
Employees3,700
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)4.90
Shares Outstanding32,438,670
10 Day Avg. Volume19,408
30 Day Avg. Volume12,281
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)2.95
Price to Sales (P/S)3.63
P/FCF Ratio-66.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.72
Revenue Forecast (FY)₹10.45B
Krsnaa Diagnostics Limited Business Overview & Revenue Model
Company Description
Krsnaa Diagnostics Limited provides diagnostic services. The company offers a range of technology-enabled diagnostic services, such as radiology, pathology/clinical laboratory, and tele-radiology services to public and private hospitals, medical c...
How the Company Makes Money
Krsnaa Diagnostics primarily earns revenue by delivering diagnostic tests and imaging services and getting paid per service rendered. A major part of its business is executed through public-private partnership (PPP) and similar service contracts w...
Krsnaa Diagnostics Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.60B | 7.17B | 6.20B | 4.87B | 4.55B | 3.96B |
| Gross Profit | 5.37B | 5.48B | 2.05B | 4.13B | 3.95B | 3.13B |
| EBITDA | 2.26B | 2.16B | 1.61B | 1.42B | 1.46B | 3.59B |
| Net Income | 845.58M | 776.08M | 568.37M | 621.11M | 683.88M | 1.85B |
Balance Sheet | ||||||
| Total Assets | 15.07B | 12.82B | 11.72B | 9.10B | 8.76B | 6.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.60B | 684.36M | 535.45M | 1.09B | 2.42B | 1.53B |
| Total Debt | 2.86B | 2.04B | 1.60B | 324.81M | 409.92M | 2.32B |
| Total Liabilities | 5.84B | 3.99B | 3.62B | 1.71B | 2.07B | 3.73B |
| Stockholders Equity | 9.23B | 8.83B | 8.10B | 7.39B | 6.84B | 2.32B |
Cash Flow | ||||||
| Free Cash Flow | -516.97M | -393.00M | -1.70B | -650.59M | -37.95M | 357.18M |
| Operating Cash Flow | 518.74M | 873.27M | 243.45M | 763.01M | 1.28B | 1.03B |
| Investing Cash Flow | -1.04B | -996.09M | -1.29B | -1.09B | -2.41B | -611.39M |
| Financing Cash Flow | 592.91M | 137.53M | 841.87M | -331.45M | 1.76B | 308.40M |
Krsnaa Diagnostics Limited Technical Analysis
Neutral
735.10
Price Trends
623.43
Negative
683.57
Negative
744.34
Negative
Market Momentum
-2.68
Negative
58.01
Neutral
93.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Neutral. The current price of 735.1 is above the 20-day moving average (MA) of 581.82, above the 50-day MA of 623.43, and below the 200-day MA of 744.34, indicating a neutral trend. The MACD of -2.68 indicates Negative momentum. The RSI at 58.01 is Neutral, neither overbought nor oversold. The STOCH value of 93.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KRSNAA.
Krsnaa Diagnostics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹114.31B | 63.11 | ― | 0.20% | 15.79% | 12.14% | |
69 Neutral | ₹64.31B | 61.22 | ― | 0.68% | 21.06% | 56.75% | |
66 Neutral | ₹234.16B | 68.44 | ― | 0.89% | 10.76% | 26.68% | |
62 Neutral | ₹14.69B | 46.67 | ― | ― | ― | ― | |
61 Neutral | ₹99.33B | 60.35 | ― | 0.21% | 18.95% | 9.30% | |
58 Neutral | ₹18.82B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KRSNAA
Krsnaa Diagnostics Limited
580.10
-130.12
-18.32%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,397.50
26.27
1.92%
IN:METROPOLIS
Metropolis Healthcare Ltd.
479.10
54.34
12.79%
IN:SURAKSHA
Suraksha Diagnostic Ltd.
282.05
-16.65
-5.57%
IN:THYROCARE
Thyrocare Technologies Ltd
404.05
111.93
38.32%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,112.80
116.16
11.66%
Krsnaa Diagnostics Limited Corporate Events
Krsnaa Diagnostics overhauls board and finance leadership in governance revamp
Apr 17, 2026
Krsnaa Diagnostics has moved to overhaul its leadership structure, with the board approving the appointment of Raju Venkatraman and Lilian Jessie Paul as additional independent directors for a two-year term, and reappointing Chetan Desai as an ind...
Krsnaa Diagnostics Shareholders Clear Five-Year Reappointment of Executive Chairman
Apr 16, 2026
Krsnaa Diagnostics Limited has secured shareholder approval via a postal ballot to reappoint founder-promoter Rajendra Khivraj Mutha as whole-time director and executive chairman for a further five-year term. The resolution, conducted through remo...
Krsnaa Diagnostics Shareholders Approve Re-Appointment of Executive Chairman
Apr 16, 2026
Krsnaa Diagnostics Limited has secured shareholder approval via postal ballot for the re-appointment of Mr. Rajendra Khivraj Mutha as whole-time director and Executive Chairman for a further five-year term. The resolution was passed with the requi...
Krsnaa Diagnostics Publishes Postal Ballot Notice for Shareholder E-Voting
Mar 17, 2026
Krsnaa Diagnostics Limited has notified stock exchanges that it has published newspaper advertisements regarding a postal ballot notice to its shareholders. The notice informs members about a proposed resolution to be approved through an e-voting-...
Krsnaa Diagnostics Extends Tenure of Executive Chairman Rajendra Mutha
Feb 22, 2026
Krsnaa Diagnostics Limited’s board has approved the re-appointment of Chairman and Whole-time Director Rajendra Khivraj Mutha as Executive Chairman for a further five-year term, effective from April 26, 2026, to April 25, 2031, subject to sh...
Krsnaa Diagnostics Reappoints Executive Chairman Rajendra Mutha for Five-Year Term
Feb 22, 2026
Krsnaa Diagnostics Limited has approved the re-appointment of Mr. Rajendra Khivraj Mutha as Whole-time Director and Chairman, designated as Executive Chairman, for a further five-year term starting April 26, 2026 and ending April 25, 2031. The dec...
Krsnaa Diagnostics Publishes Q3 FY26 Earnings Call Transcript
Feb 11, 2026
Krsnaa Diagnostics Limited has released the transcript of its earnings conference call discussing unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The call, held on February 6, 2026 w...
Krsnaa Diagnostics Plans Mumbai Investor Meeting Under SEBI Norms
Feb 10, 2026
Krsnaa Diagnostics has scheduled a one-on-one physical meeting with investors and analysts hosted by Akash Ganga Limited in Mumbai on February 13, 2026, starting at 11:00 a.m. IST. The company emphasized that the interaction will be confined to pu...
Krsnaa Diagnostics Publishes Unaudited Q3 and Nine-Month FY26 Results in Newspapers
Feb 7, 2026
Krsnaa Diagnostics Limited has published newspaper advertisements of its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 in the English daily Financial Express and Marathi daily Loksat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.